Form 10-Q Spero Therapeutics, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
TD Cowen Upgrades Spero Therapeutics (SPRO) to Buy
August 6, 2024 7:22 AM EDTTD Cowen analyst Ritu Baral upgraded Spero Therapeutics (NASDAQ: SPRO) from Hold to Buy.
The analyst comments "2Q24: We are upgrading SPRO to Buy on new clarity on catalyst timing and optimism for '720 Ph2a data in the 2nd half of... More



